title: Randomized trial of infusion set function: steel versus teflon.
abstract: BACKGROUND
  This study compared infusion set function for up to 1 week using either a Teflon(®) (Dupont(™), Wilmington, DE) catheter or a steel catheter for insulin pump therapy in type 1 diabetes mellitus.
  
  
  METHODS
  Twenty subjects participating in a randomized, open-labeled, crossover study were asked to wear two Quick-Set(®) and two Sure-T(®) infusion sets (both from Medtronic Minimed, Northridge, CA) until the infusion set failed or was worn for 1 week. All subjects wore a MiniMed continuous glucose monitoring system for the duration of the study.
  
  
  RESULTS
  One subject withdrew from the study. There were 38 weeks of Sure-T wear and 39 weeks of Quick-Set wear with no difference in the survival curves of the infusion sets. There was, however, a 15% initial failure rate with the Teflon infusion set. After 7 days, both types of infusion sets had a 64% failure rate. Overall, 30% failed because of hyperglycemia and a failed correction dose, 13% were removed for pain, 10% were pulled out by accident, 10% had erythema and/or induration of>10 mm, 5% fell out because of loss of adhesion, and 4% were removed for infection. The main predictor of length of wear was the individual subject. There was no increase in hyperglycemia or daily insulin requirements when an infusion set was successfully used for 7 days (n=25 of 77 weeks).
  
  
  CONCLUSIONS
  We found no difference between steel and Teflon infusion sets in their function over 7 days, although 15% of Teflon sets failed because of kinking on insertion. The strongest predictor of prolonged 7-day infusion set function was the individual subject, not the type of infusion set.
authors.affiliation: Department of Pediatric Endocrinology, Stanford Medical Center , Stanford, California.
authors.forename: Parul J
authors.initials: PJ
authors.lastname: Patel
authors.forename: Kari
authors.initials: K
authors.lastname: Benasi
authors.forename: Gina
authors.initials: G
authors.lastname: Ferrari
authors.forename: Mark G
authors.initials: MG
authors.lastname: Evans
authors.forename: Satya
authors.initials: S
authors.lastname: Shanmugham
authors.forename: Darrell M
authors.initials: DM
authors.lastname: Wilson
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Buckingham
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015190:Blood Glucose Self-Monitoring; D015992:Body Mass Index; D002404:Catheterization; D002648:Child; D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004867:Equipment Design; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007262:Infusions, Intravenous / Q000295:instrumentation* / Q000379:methods; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D011138:Polytetrafluoroethylene; D013232:Steel; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D011138:Polytetrafluoroethylene; D013232:Steel; C517652:hemoglobin A1c protein, human